BioCryst Pharmaceuticals (BCRX) Sees Unusually-High Trading Volume

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) saw unusually-high trading volume on Friday . Approximately 3,973,376 shares changed hands during trading, an increase of 160% from the previous session’s volume of 1,529,526 shares.The stock last traded at $5.00 and had previously closed at $4.85.

BCRX has been the topic of a number of research analyst reports. Piper Jaffray Companies restated an “overweight” rating and set a $15.00 price target (up previously from $13.00) on shares of BioCryst Pharmaceuticals in a research note on Tuesday, September 5th. ValuEngine upgraded BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, August 28th. HC Wainwright restated a “buy” rating and set a $10.00 price target on shares of BioCryst Pharmaceuticals in a research note on Wednesday, September 6th. J P Morgan Chase & Co boosted their price target on BioCryst Pharmaceuticals from $4.93 to $9.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 6th. Finally, Royal Bank of Canada began coverage on BioCryst Pharmaceuticals in a research note on Thursday, September 14th. They set a “sector perform” rating and a $6.00 price target on the stock. Two analysts have rated the stock with a sell rating, four have given a hold rating and six have assigned a buy rating to the stock. BioCryst Pharmaceuticals presently has a consensus rating of “Hold” and an average price target of $9.00.

The company has a debt-to-equity ratio of 0.21, a quick ratio of 2.53 and a current ratio of 2.53.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.18) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.18). The firm had revenue of $8.76 million for the quarter, compared to analyst estimates of $5.05 million. BioCryst Pharmaceuticals had a negative return on equity of 123.16% and a negative net margin of 167.58%. BioCryst Pharmaceuticals’s revenue for the quarter was up 12.9% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($0.16) earnings per share. sell-side analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.71 earnings per share for the current fiscal year.

In related news, Director Fred E. Cohen sold 54,250 shares of the company’s stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $5.42, for a total value of $294,035.00. Following the sale, the director now owns 173,660 shares in the company, valued at $941,237.20. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, CMO William P. Sheridan sold 64,310 shares of the company’s stock in a transaction that occurred on Monday, November 13th. The shares were sold at an average price of $4.72, for a total value of $303,543.20. The disclosure for this sale can be found here. 5.80% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in BCRX. Renaissance Technologies LLC boosted its position in BioCryst Pharmaceuticals by 339.3% in the 1st quarter. Renaissance Technologies LLC now owns 219,203 shares of the biotechnology company’s stock worth $1,841,000 after purchasing an additional 169,300 shares in the last quarter. Schwab Charles Investment Management Inc. boosted its position in BioCryst Pharmaceuticals by 23.2% in the 1st quarter. Schwab Charles Investment Management Inc. now owns 333,373 shares of the biotechnology company’s stock worth $2,801,000 after purchasing an additional 62,792 shares in the last quarter. Bank of America Corp DE boosted its position in BioCryst Pharmaceuticals by 43.3% in the 1st quarter. Bank of America Corp DE now owns 25,029 shares of the biotechnology company’s stock worth $210,000 after purchasing an additional 7,568 shares in the last quarter. Credit Suisse AG boosted its position in BioCryst Pharmaceuticals by 71.5% in the 1st quarter. Credit Suisse AG now owns 110,837 shares of the biotechnology company’s stock worth $931,000 after purchasing an additional 46,204 shares in the last quarter. Finally, Janney Montgomery Scott LLC boosted its position in BioCryst Pharmaceuticals by 4.7% in the 2nd quarter. Janney Montgomery Scott LLC now owns 33,335 shares of the biotechnology company’s stock worth $185,000 after purchasing an additional 1,500 shares in the last quarter. Institutional investors and hedge funds own 84.69% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was published by Community Financial News and is owned by of Community Financial News. If you are viewing this article on another domain, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this article can be viewed at https://www.com-unik.info/2017/12/17/biocryst-pharmaceuticals-bcrx-sees-unusually-high-trading-volume-2.html.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

What are top analysts saying about BioCryst Pharmaceuticals? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for BioCryst Pharmaceuticals and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit